1
|
Collier-Bain HD, Emery A, Causer AJ, Brown FF, Oliver R, Dutton D, Crowe J, Augustine D, Graby J, Leach S, Eddy R, Rothschild-Rodriguez D, Gray JC, Cragg MS, Cleary KL, Moore S, Murray J, Turner JE, Campbell JP. A single bout of vigorous intensity exercise enhances the efficacy of rituximab against human chronic lymphocytic leukaemia B-cells ex vivo. Brain Behav Immun 2024; 118:468-479. [PMID: 38503395 DOI: 10.1016/j.bbi.2024.03.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/18/2023] [Revised: 02/15/2024] [Accepted: 03/16/2024] [Indexed: 03/21/2024] Open
Abstract
Chronic lymphocytic leukaemia (CLL) is characterised by the clonal proliferation and accumulation of mature B-cells and is often treated with rituximab, an anti-CD20 monoclonal antibody immunotherapy. Rituximab often fails to induce stringent disease eradication, due in part to failure of antibody-dependent cellular cytotoxicity (ADCC) which relies on natural killer (NK)-cells binding to rituximab-bound CD20 on B-cells. CLL cells are diffusely spread across lymphoid and other bodily tissues, and ADCC resistance in survival niches may be due to several factors including low NK-cell frequency and a suppressive stromal environment that promotes CLL cell survival. It is well established that exercise bouts induce a transient relocation of NK-cells and B-cells into peripheral blood, which could be harnessed to enhance the efficacy of rituximab in CLL by relocating both target and effector cells together with rituximab in blood. In this pilot study, n = 20 patients with treatment-naïve CLL completed a bout of cycling 15 % above anaerobic threshold for ∼ 30-minutes, with blood samples collected pre-, immediately post-, and 1-hour post-exercise. Flow cytometry revealed that exercise evoked a 254 % increase in effector (CD3-CD56+CD16+) NK-cells in blood, and a 67 % increase in CD5+CD19+CD20+ CLL cells in blood (all p < 0.005). NK-cells were isolated from blood samples pre-, and immediately post-exercise and incubated with primary isolated CLL cells with or without the presence of rituximab to determine specific lysis using a calcein-release assay. Rituximab-mediated cell lysis increased by 129 % following exercise (p < 0.001). Direct NK-cell lysis of CLL cells - independent of rituximab - was unchanged following exercise (p = 0.25). We conclude that exercise improved the efficacy of rituximab-mediated ADCC against autologous CLL cells ex vivo and propose that exercise should be explored as a means of enhancing clinical responses in patients receiving anti-CD20 immunotherapy.
Collapse
Affiliation(s)
| | | | - Adam J Causer
- Department for Health, University of Bath, United Kingdom
| | - Frankie F Brown
- Department for Health, University of Bath, United Kingdom; School of Applied Sciences, Edinburgh Napier University, Edinburgh, United Kingdom
| | - Rebecca Oliver
- Department for Health, University of Bath, United Kingdom; Department for Haematology, Royal United Hospitals Bath NHS Foundation Trust, United Kingdom
| | - David Dutton
- Department for Haematology, Great Western Hospitals NHS Foundation Trust, United Kingdom
| | - Josephine Crowe
- Department for Haematology, Royal United Hospitals Bath NHS Foundation Trust, United Kingdom
| | - Daniel Augustine
- Department of Cardiology, Royal United Hospitals Bath NHS Foundation Trust, United Kingdom
| | - John Graby
- Department for Health, University of Bath, United Kingdom; Department of Cardiology, Royal United Hospitals Bath NHS Foundation Trust, United Kingdom
| | - Shoji Leach
- Department for Health, University of Bath, United Kingdom
| | - Rachel Eddy
- Department for Health, University of Bath, United Kingdom
| | | | - Juliet C Gray
- Antibody and Vaccine Group, Centre for Cancer Immunology, University of Southampton, United Kingdom
| | - Mark S Cragg
- Antibody and Vaccine Group, Centre for Cancer Immunology, University of Southampton, United Kingdom
| | - Kirstie L Cleary
- Antibody and Vaccine Group, Centre for Cancer Immunology, University of Southampton, United Kingdom
| | - Sally Moore
- Department for Haematology, Royal United Hospitals Bath NHS Foundation Trust, United Kingdom
| | - James Murray
- Department for Haematology, Royal United Hospitals Bath NHS Foundation Trust, United Kingdom
| | - James E Turner
- Department for Health, University of Bath, United Kingdom; School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, United Kingdom
| | - John P Campbell
- Department for Health, University of Bath, United Kingdom; School of Medical and Health Sciences, Edith Cowan University, Perth, Australia.
| |
Collapse
|
2
|
Graby J, Khavandi A, Gillison F, Smith T, Murphy D, Peacock O, McLeod H, Dastidar A, Antoniades C, Thompson D, Rodrigues JCL. 'Super Rehab': can we achieve coronary artery disease regression? A feasibility study protocol. BMJ Open 2023; 13:e080735. [PMID: 38086597 PMCID: PMC10729239 DOI: 10.1136/bmjopen-2023-080735] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/10/2023] [Accepted: 10/31/2023] [Indexed: 12/18/2023] Open
Abstract
INTRODUCTION Patients diagnosed with coronary artery disease (CAD) are currently treated with medications and lifestyle advice to reduce the likelihood of disease progression and risk of future major adverse cardiovascular events (MACE). Where obstructive disease is diagnosed, revascularisation may be considered to treat refractory symptoms. However, many patients with coexistent cardiovascular risk factors, particularly those with metabolic syndrome (MetS), remain at heightened risk of future MACE despite current management.Cardiac rehabilitation is offered to patients post-revascularisation, however, there is no definitive evidence demonstrating its benefit in a primary prevention setting. We propose that an intensive lifestyle intervention (Super Rehab, SR) incorporating high-intensity exercise, diet and behavioural change techniques may improve symptoms, outcomes, and enable CAD regression.This study aims to examine the feasibility of delivering a multicentre randomised controlled trial (RCT) testing SR for patients with CAD, in a primary prevention setting. METHODS AND ANALYSIS This is a multicentre randomised controlled feasibility study of SR versus usual care in patients with CAD. The study aims to recruit 50 participants aged 18-75 across two centres. Feasibility will be assessed against rates of recruitment, retention and, in the intervention arm, attendance and adherence to SR. Qualitative interviews will explore trial experiences of study participants and practitioners. Variance of change in CAD across both arms of the study (assessed with serial CT coronary angiography) will inform the design and power of a future, multi-centre RCT. ETHICS AND DISSEMINATION Ethics approval was granted by South West-Frenchay Research Ethics Committee (reference: 21/SW/0153, 18 January 2022). Study findings will be disseminated via presentations to relevant stakeholders, national and international conferences and open-access peer-reviewed research publications. TRIAL REGISTRATION NUMBER ISRCTN14603929.
Collapse
Affiliation(s)
- John Graby
- Cardiology, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK
- Health, University of Bath, Bath, UK
| | - Ali Khavandi
- Cardiology, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK
| | | | | | - David Murphy
- Cardiology, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK
- Health, University of Bath, Bath, UK
| | | | | | | | - Charalambos Antoniades
- Acute Multidisciplinary Imaging & Interventional Centre, University of Oxford, John Radcliffe Hospital, Oxford, UK
| | | | | |
Collapse
|
3
|
Murphy D, Stephenson J, Bouhbib Y, Graby J, Khavandi A, Lyen S, Hudson B, Rodrigues JCL. Investigating the impact of non-gated thoracic CT prior to CTCA to reduce layered testing. Clin Radiol 2023; 78:947-954. [PMID: 37718182 DOI: 10.1016/j.crad.2023.08.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2023] [Revised: 08/15/2023] [Accepted: 08/16/2023] [Indexed: 09/19/2023]
Abstract
AIM To determine the proportion of computed tomography (CT) coronary angiography (CTCA) referrals with coronary artery calcification (CAC) evident on previous non-cardiac CT imaging and how this impacted the diagnostic yield for CTCA, the requirement for additional diagnostic testing, and the associated costs to confirm or refute obstructive coronary artery disease (CAD). MATERIALS AND METHODS A retrospective review of CTCA examinations was undertaken between 01/05/2018 and 31/05/2020 in which the examinations were cross referenced for previous non-gated thoracic CT at Royal United Hospitals Bath. Major epicardial vessel CAC on baseline CT was re-evaluated by published semi-quantitative methods, giving a per-patient CAC score (mild = 1-3, moderate = 4-6, severe >6). Subsequent incomplete CTCA diagnostic yield, further testing, and cost implications were examined. RESULTS Of the 2140 CTCA examinations identified, 13% (280/2140) had a preceding non-gated thoracic CT (53% female, age 63 ± 11 years). The incomplete diagnostic rate increased with CAC grade, mild 32%, (RR 12; 95% CI 4-40), moderate 64% (RR 25; 95% CI 8-80), severe 75%, (RR 29; 95% CI 9-94). Additional diagnostic testing occurred in 4% for the mild CAC category, and 14% and 42% for moderate and severe, respectively. When severe CAC was identified on a non-gated thoracic CT a cost saving of £171/patient (dobutamine stress echo [DSE]) and £61/patient (myocardial perfusion scintigraphy [MPS]) was established with a direct to functional testing pathway. CONCLUSIONS In patients referred for CTCA where severe CAC was identified on a preceding non-gated thoracic CT a direct to functional testing altered management in 42% of cases and was cost-effective.
Collapse
Affiliation(s)
- D Murphy
- Department of Cardiology, Royal United Hospitals Bath, Bath, UK; Department for Health, University of Bath, Bath, UK
| | - J Stephenson
- Department of Cardiology, Royal United Hospitals Bath, Bath, UK
| | - Y Bouhbib
- Department of Radiology, Royal United Hospitals Bath, Bath, UK
| | - J Graby
- Department of Cardiology, Royal United Hospitals Bath, Bath, UK; Department for Health, University of Bath, Bath, UK
| | - A Khavandi
- Department of Cardiology, Royal United Hospitals Bath, Bath, UK
| | - S Lyen
- Department of Radiology, Royal United Hospitals Bath, Bath, UK
| | - B Hudson
- Department of Radiology, Royal United Hospitals Bath, Bath, UK
| | - J C L Rodrigues
- Department for Health, University of Bath, Bath, UK; Department of Radiology, Royal United Hospitals Bath, Bath, UK.
| |
Collapse
|
4
|
Graby J, Harris M, Jones C, Waring H, Lyen S, Hudson BJ, Rodrigues JCL. Assessing the role of an artificial intelligence assessment tool for thoracic aorta diameter on routine chest CT. Br J Radiol 2023; 96:20220853. [PMID: 37335231 PMCID: PMC10607407 DOI: 10.1259/bjr.20220853] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2022] [Revised: 02/19/2023] [Accepted: 04/02/2023] [Indexed: 06/21/2023] Open
Abstract
OBJECTIVE To assess the diagnostic accuracy and clinical impact of automated artificial intelligence (AI) measurement of thoracic aorta diameter on routine chest CT. METHODS A single-centre retrospective study involving three cohorts. 210 consecutive ECG-gated CT aorta scans (mean age 75 ± 13) underwent automated analysis (AI-Rad Companion Chest CT, Siemens) and were compared to a reference standard of specialist cardiothoracic radiologists for accuracy measuring aortic diameter. A repeated measures analysis tested reporting consistency in a second cohort (29 patients, mean age 61 ± 17) of immediate sequential pre-contrast and contrast CT aorta acquisitions. Potential clinical impact was assessed in a third cohort of 197 routine CT chests (mean age 66 ± 15) to document potential clinical impact. RESULTS AI analysis produced a full report in 387/436 (89%) and a partial report in 421/436 (97%). Manual vs AI agreement was good to excellent (ICC 0.76-0.92). Repeated measures analysis of expert and AI reports for the ascending aorta were moderate to good (ICC 0.57-0.88). AI diagnostic performance crossed the threshold for maximally accepted limits of agreement (>5 mm) at the aortic root on ECG-gated CTs. AI newly identified aortic dilatation in 27% of patients on routine thoracic imaging with a specificity of 99% and sensitivity of 77%. CONCLUSION AI has good agreement with expert readers at the mid-ascending aorta and has high specificity, but low sensitivity, at detecting dilated aortas on non-dedicated chest CTs. ADVANCES IN KNOWLEDGE An AI tool may improve the detection of previously unknown thoracic aorta dilatation on chest CTs vs current routine reporting.
Collapse
Affiliation(s)
| | - Maredudd Harris
- Department of Radiology, Royal United Hospital, Bath, United Kingdom
| | - Calum Jones
- Department of Radiology, Royal United Hospital, Bath, United Kingdom
| | - Harry Waring
- Department of Radiology, Royal United Hospital, Bath, United Kingdom
| | - Stephen Lyen
- Department of Radiology, Royal United Hospital, Bath, United Kingdom
| | - Benjamin J Hudson
- Department of Radiology, Royal United Hospital, Bath, United Kingdom
| | | |
Collapse
|
5
|
Helbrow J, Graby J, Lewis G, Cox S, Nicholas O, Radhakrishna G, Crosby T, Gwynne S. Dose Escalation in Esophageal Cancer: Comparing Pre-Accrual and On-Trial Target Volume Delineation in the UK SCOPE2 Trial. Int J Radiat Oncol Biol Phys 2023; 117:e301-e302. [PMID: 37785101 DOI: 10.1016/j.ijrobp.2023.06.2318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) The ongoing UK SCOPE2 trial evaluates radiotherapy (RT) dose escalation and PET-guided systemic therapy in esophageal cancer, and has an accompanying RT trials quality assurance (RTTQA) program, evolved through the preceding SCOPE trials. We compare pre-accrual with on-trial individual case review (ICR) target volume delineation (TVD). MATERIALS/METHODS Prior to recruitment, centers were required to undertake TVD exercises using 3D/4D DICOM datasets with relevant clinical details and a RT planning guidance document (RPGD) provided. Contours were then compared against the RTTQA team-defined gold standard. Exceptions were those who had satisfied QA requirements for a previous esophageal RT trial (NeoSCOPE). For ICRs, prospective reviews (prior RT start, PRs) were undertaken for each center's first submission, plus high-dose cases submitted pending formal safety review. Additional PRs were undertaken at the RTTQA team's discretion. Timely retrospective reviews (within 2 weeks of RT start, TRR) were also undertaken for a random 10% sample. TVDs were assessed for compliance using predefined criteria and the RPGD. Resubmission was requested at reviewer's discretion, usually due to unacceptable variation (UV) from protocol. Clarification was sought before contour approval/resubmission request if appropriate. Review outcomes were then evaluated. PTV6000 was new to SCOPE2, along with a greater emphasis on use of 4DCT than in prior SCOPE trials. RESULTS A total of 85 pre-accrual cases from 33 UK centers were reviewed, of which 20 (24%) were resubmissions, and 50 (59%) were accepted. 99 TVD UVs were observed in 49 cases, most commonly in CTVB (42/99, 42%), which included editing for normal structures and elective lymph node regions, followed by ITV (4D cases only, 14/52, 27%) and PTV6000 (13/99, 13%). 121 ICRs from 31 UK centers were available for review. 87 (72%) were PRs and 34 (28%) TRRs. 43 (36%) completed the relevant SCOPE2 exercise. 19 (16%) were resubmissions, and 82 (68%) were accepted. 72 UVs were observed in 45 ICRs; again, most commonly in CTVB (34/72, 48%), PTV6000 (high dose arm only, 11/46, 24%) and ITV (4D only, 5/26, 19%). Of the 45 cases where a UV was recorded, 16 (36%) had completed the relevant SCOPE2 pre-accrual. Comparing area of UV on SCOPE2 pre-accrual cases and ICRs, 3 (19%) contours contained the same (2 = CTVB, 1 = PTV6000), 5 (31%) contained different and 8 (50%) had no UVs at pre-accrual. The rate of UV was significantly lower for ICR than for pre-accrual submissions (0.60 and 1.16 respectively, p = 0.001). CONCLUSION Significantly fewer UVs in ICR compared with pre-accrual supports a robust, educational RTTQA program through national collaboration and evolving trial series. CTVB, along with newer volumes of ITV and PTV6000, were recurring UV domains and should inform RPGD development and RTTQA for ongoing recruitment and future trials.
Collapse
Affiliation(s)
- J Helbrow
- South West Wales Cancer Centre, Swansea, United Kingdom
| | - J Graby
- University of Bath, Bath, United Kingdom
| | - G Lewis
- Velindre Cancer Centre, Cardiff, United Kingdom
| | - S Cox
- Velindre Cancer Centre, Cardiff, United Kingdom
| | - O Nicholas
- South West Wales Cancer Centre, Swansea, United Kingdom; Swansea University, Swansea, United Kingdom
| | | | - T Crosby
- Velindre Cancer Centre, Cardiff, United Kingdom
| | - S Gwynne
- South West Wales Cancer Centre, Swansea, United Kingdom; Swansea University, Swansea, United Kingdom
| |
Collapse
|
6
|
West HW, Siddique M, Williams MC, Volpe L, Desai R, Lyasheva M, Thomas S, Dangas K, Kotanidis CP, Tomlins P, Mahon C, Kardos A, Adlam D, Graby J, Rodrigues JCL, Shirodaria C, Deanfield J, Mehta NN, Neubauer S, Channon KM, Desai MY, Nicol ED, Newby DE, Antoniades C. Deep-Learning for Epicardial Adipose Tissue Assessment With Computed Tomography: Implications for Cardiovascular Risk Prediction. JACC Cardiovasc Imaging 2023; 16:800-816. [PMID: 36881425 PMCID: PMC10663979 DOI: 10.1016/j.jcmg.2022.11.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/17/2022] [Revised: 11/09/2022] [Accepted: 11/17/2022] [Indexed: 02/11/2023]
Abstract
BACKGROUND Epicardial adipose tissue (EAT) volume is a marker of visceral obesity that can be measured in coronary computed tomography angiograms (CCTA). The clinical value of integrating this measurement in routine CCTA interpretation has not been documented. OBJECTIVES This study sought to develop a deep-learning network for automated quantification of EAT volume from CCTA, test it in patients who are technically challenging, and validate its prognostic value in routine clinical care. METHODS The deep-learning network was trained and validated to autosegment EAT volume in 3,720 CCTA scans from the ORFAN (Oxford Risk Factors and Noninvasive Imaging Study) cohort. The model was tested in patients with challenging anatomy and scan artifacts and applied to a longitudinal cohort of 253 patients post-cardiac surgery and 1,558 patients from the SCOT-HEART (Scottish Computed Tomography of the Heart) Trial, to investigate its prognostic value. RESULTS External validation of the deep-learning network yielded a concordance correlation coefficient of 0.970 for machine vs human. EAT volume was associated with coronary artery disease (odds ratio [OR] per SD increase in EAT volume: 1.13 [95% CI: 1.04-1.30]; P = 0.01), and atrial fibrillation (OR: 1.25 [95% CI: 1.08-1.40]; P = 0.03), after correction for risk factors (including body mass index). EAT volume predicted all-cause mortality (HR per SD: 1.28 [95% CI: 1.10-1.37]; P = 0.02), myocardial infarction (HR: 1.26 [95% CI:1.09-1.38]; P = 0.001), and stroke (HR: 1.20 [95% CI: 1.09-1.38]; P = 0.02) independently of risk factors in SCOT-HEART (5-year follow-up). It also predicted in-hospital (HR: 2.67 [95% CI: 1.26-3.73]; P ≤ 0.01) and long-term post-cardiac surgery atrial fibrillation (7-year follow-up; HR: 2.14 [95% CI: 1.19-2.97]; P ≤ 0.01). CONCLUSIONS Automated assessment of EAT volume is possible in CCTA, including in patients who are technically challenging; it forms a powerful marker of metabolically unhealthy visceral obesity, which could be used for cardiovascular risk stratification.
Collapse
Affiliation(s)
- Henry W West
- Acute Multidisciplinary Imaging and Interventional Centre, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom; Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom
| | - Muhammad Siddique
- Acute Multidisciplinary Imaging and Interventional Centre, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom; Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom; Caristo Diagnostics Pty Ltd, Oxford, United Kingdom
| | - Michelle C Williams
- Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, Scotland, United Kingdom
| | - Lucrezia Volpe
- Acute Multidisciplinary Imaging and Interventional Centre, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom; Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom
| | - Ria Desai
- Northwestern University, Evanston, Illinois, USA
| | - Maria Lyasheva
- Acute Multidisciplinary Imaging and Interventional Centre, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom; Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom
| | - Sheena Thomas
- Acute Multidisciplinary Imaging and Interventional Centre, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom; Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom
| | - Katerina Dangas
- Acute Multidisciplinary Imaging and Interventional Centre, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom; Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom
| | - Christos P Kotanidis
- Acute Multidisciplinary Imaging and Interventional Centre, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom
| | - Pete Tomlins
- Acute Multidisciplinary Imaging and Interventional Centre, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom; Caristo Diagnostics Pty Ltd, Oxford, United Kingdom
| | - Ciara Mahon
- Royal Brompton and Harefield National Health Service (NHS) Foundation Trust, London, United Kingdom
| | - Attila Kardos
- Translational Cardiovascular Research Group, Department of Cardiology, Milton Keynes University Hospital, Milton Keynes, United Kingdom; Faculty of Medicine and Health Sciences, University of Buckingham, Buckingham, United Kingdom
| | - David Adlam
- Department of Cardiovascular Sciences and National Institute for Health Research Leicester Biomedical Research Centre, University of Leicester, Leicester, United Kingdom
| | - John Graby
- Royal United Hospitals Bath NHS Foundation Trust, Bath, United Kingdom
| | - Jonathan C L Rodrigues
- Royal United Hospitals Bath NHS Foundation Trust, Bath, United Kingdom; Department of Health, University of Bath, Bath, United Kingdom
| | - Cheerag Shirodaria
- Caristo Diagnostics Pty Ltd, Oxford, United Kingdom; Department of Cardiology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
| | | | - Nehal N Mehta
- National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
| | - Stefan Neubauer
- Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom; Department of Cardiology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
| | - Keith M Channon
- Acute Multidisciplinary Imaging and Interventional Centre, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom; Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom; Department of Cardiology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
| | | | - Edward D Nicol
- Royal Brompton and Harefield National Health Service (NHS) Foundation Trust, London, United Kingdom; School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom
| | - David E Newby
- Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, Scotland, United Kingdom
| | - Charalambos Antoniades
- Acute Multidisciplinary Imaging and Interventional Centre, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom; Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom; Department of Cardiology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
| |
Collapse
|
7
|
Graby J, Murphy D, Metters R, Parke K, Jones S, Ellis D, Khavandi A, Carson K, Lowe R, Rodrigues JC. CT coronary angiography first prior to rapid access chest pain clinic review: a retrospective feasibility study. Br J Radiol 2023; 96:20220201. [PMID: 36377676 PMCID: PMC9975380 DOI: 10.1259/bjr.20220201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2022] [Revised: 08/12/2022] [Accepted: 09/08/2022] [Indexed: 11/16/2022] Open
Abstract
OBJECTIVES Since rapid access chest pain clinics (RACPC) were established to streamline stable chest pain assessment, CT coronary angiography (CTCA) has become the recommended investigation for patients without known coronary artery disease (CAD), with well-defined indications. This single-centre retrospective study assessed the feasibility of General Practice (GP)-led CTCA prior to RACPC. METHODS RACPC pathway patients without pre-existing CAD electronic records were reviewed (September-October 2019). Feasibility assessments included appropriateness for RACPC, referral clinical data vs RACPC assessment for CTCA indication and safety, and a comparison of actual vs hypothetical pathways, timelines and hospital encounters. RESULTS 106/172 patients screened met inclusion criteria (mean age 61 ± 14, 51% female). 102 (96%) referrals were 'appropriate'. No safety concerns were identified to preclude a GP-led CTCA strategy. The hypothetical pathway increased CTCA requests vs RACPC (84 vs 71), whilst improving adherence to guidelines and off-loading other services. 22% (23/106) had no CAD, representing cases where one hospital encounter may be sufficient. The hypothetical pathway would have reduced referral-to-diagnosis by at least a median of 27 days (interquartile range 14-33). CONCLUSION A hypothetical GP-led CTCA pathway would have been feasible and safe in a real-world RACPC patient cohort without pre-existing CAD. This novel strategy would have increased referrals for CTCA, whilst streamlining patient pathways and improved NICE guidance adherence. ADVANCES IN KNOWLEDGE GP-led CTCA is a feasible and safe pathway for patients without pre-existing CAD referred to RACPC, reducing hospital encounters required and may accelerate time to diagnosis. This approach may have implications and opportunities for other healthcare pathways.
Collapse
Affiliation(s)
| | - David Murphy
- Department of Cardiology, Royal United Hospital, Combe Park, Bath, United Kingdom
| | - Rhys Metters
- Department of Cardiology, Royal United Hospital, Combe Park, Bath, United Kingdom
| | - Kady Parke
- Department of Cardiology, Royal United Hospital, Combe Park, Bath, United Kingdom
| | - Samantha Jones
- Department of Cardiology, Royal United Hospital, Combe Park, Bath, United Kingdom
| | - Dawn Ellis
- Department of Cardiology, Royal United Hospital, Combe Park, Bath, United Kingdom
| | - Ali Khavandi
- Department of Cardiology, Royal United Hospital, Combe Park, Bath, United Kingdom
| | - Kevin Carson
- Department of Cardiology, Royal United Hospital, Combe Park, Bath, United Kingdom
| | - Rob Lowe
- Department of Cardiology, Royal United Hospital, Combe Park, Bath, United Kingdom
| | | |
Collapse
|
8
|
Barrishi A, Graby J, Khavandi A, Dastidar A, Rodrigues JCL. Assessing splenic switch-off in Adenosine stress CMR for patients with atrial fibrillation: a propensity-matched study. Br J Radiol 2022; 95:20220422. [PMID: 36000672 PMCID: PMC9793484 DOI: 10.1259/bjr.20220422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
OBJECTIVES Splenic switch-off (SSO) is a validated indicator of adequate vasodilator stress unique to adenosine stress cardiac MR (CMR). Patients in atrial fibrillation (AF) may have a reduced adenosine response due to lower hyperaemic coronary flow reserve and may achieve SSO less frequently versus sinus rhythm (SR). METHODS 1100 stress CMR studies were identified from a clinical CMR database (2016-2021). 70 patients in AF were propensity score matched to a SR group for age, sex, and body mass index. The adenosine dose administered, symptoms, heart-rate change and scan result were recorded. SSO was evaluated subjectively and semi-quantitatively via changes in splenic and myocardial signal intensity (SI) from rest to stress. RESULTS SSO occurred significantly less frequently in AF than SR (34/70 [49%] vs 53/70 [76%], p = 0.003). Semi-quantitative assessment supported this, with a smaller splenic SI difference between stress and rest in AF vs SR (median splenic stress:rest peak SI ratio 0.92 [IQR:0.61-1.11] vs 0.56 [IQR:0.45-0.75], p < 0.001). A heart-rate increase >10 bpm predicted visual SSO in SR but not AF. Fewer patients in AF than SR had inducible ischaemia (9/70 [13%] vs 17/69 [25%], p = 0.058). This difference was not driven by inducible ischaemia rates in patients who did not achieve SSO (6/36 [17%] AF vs 4/17 [24%] SR, p = 0.403). CONCLUSIONS SSO occurs significantly less frequently with AF. This may risk the under diagnosis of inducible ischaemia and requires further assessment. ADVANCES IN KNOWLEDGE SSO, a validated marker of adequate stress in CMR, occurs significantly less frequently in the presence of AF, risking a suboptimal functional assessment of coronary disease.
Collapse
Affiliation(s)
| | | | - Ali Khavandi
- Department of Cardiology, Royal United Hospital, Combe Park, Bath, UK
| | - Amardeep Dastidar
- Department of Cardiology, North Bristol NHS Trust, Southmead Rd, Bristol, UK
| | | |
Collapse
|
9
|
Graby J, Sellek J, Khavandi A, Loughborough W, Hudson BJ, Shirodaria C, Downie P, Antoniades C, Rodrigues JCL. Coronary CT angiography derived pericoronary inflammation and bespoke cardiovascular risk prediction in the lipid clinic: beyond the calcium score. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Dyslipidaemia promotes atherosclerosis. Genetic dyslipidaemias, Familial Hypercholesterolaemia (FH) being the most common, are associated with heightened risk of coronary artery disease (CAD) and premature major adverse cardiovascular events (MACE). However, this risk is both heterogeneous and modifiable with treatment.
CT coronary imaging can identify subclinical atherosclerosis, enabling personalised risk stratification and treatment targets. Coronary artery calcium scoring (CACS) is current first-line in European guidelines for asymptomatic patients. However, calcification occurs late in CAD pathogenesis and CACS has low specificity in young patients with severe FH. CT coronary angiography (CTCA) assesses non-calcific plaque and high-risk plaque (HRP) features unappreciable with CACS. Additionally, the pericoronary fat attenuation index (FAI) measures inflammation on routine CTCA and is the strongest non-invasive imaging biomarker of risk of fatal MI.
Purpose
To quantify and compare the reclassification of subclinical atherosclerosis burden in Lipid Clinic patients assessed via CACS vs CTCA with FAI analysis.
Methods
Analysis of a prospectively maintained clinical database of asymptomatic Lipid Clinic patients with both CACS and CTCA imaging from May 2019 to December 2020. CACS was reported with the standardised Agastston criteria and compared with (i) the CTCA-derived Coronary Artery Disease – Reporting and Data System (CAD RADS) grading of anatomical stenosis, including a modifier for HRP features, and (ii) FAI analysis. Significance was defined as two-tailed p75th percentile vs age and sex matched controls) was seen in 6/27 (22%) patients with none to mild calcification on CACS and 6/28 (21%) patients with none to mild CAD on CTCA, of whom 3/7 (43%) had HRP. High FAI was seen in all groups of calcification severity and CAD RADS score (Figure 2). The proportion with high FAI was higher in CAD RADS 0 vs CAD RADS 4, and CACS severity was not associated with level of inflammation (p=0.94).
High FAI was observed in 16% of patients on treatment, suggesting treatment failure. This included patients with CACS ranging from 0 to severe (>400), and CAD RADS of minimal (1) to severe (4).
Conclusion
CTCA re-stratifies CAD presence and severity vs CACS in a high-risk, asymptomatic patient group and identified a high proportion of patients with HRP features. FAI provides incremental value in identification of patients at risk of future MACE regardless of CACS grade, including patients without evidence of overt CAD. Identifying high FAI on treatment may imply treatment failure.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- J Graby
- Royal United Hospital Bath NHS Trust , Bath , United Kingdom
| | - J Sellek
- Royal United Hospital Bath NHS Trust , Bath , United Kingdom
| | - A Khavandi
- Royal United Hospital Bath NHS Trust , Bath , United Kingdom
| | - W Loughborough
- Royal United Hospital Bath NHS Trust , Bath , United Kingdom
| | - B J Hudson
- Royal United Hospital Bath NHS Trust , Bath , United Kingdom
| | - C Shirodaria
- Oxford University Hospitals NHS Foundation Trust , Oxford , United Kingdom
| | - P Downie
- Salisbury Hospital NHS Trust , Salisbury , United Kingdom
| | | | - J C L Rodrigues
- Royal United Hospital Bath NHS Trust , Bath , United Kingdom
| |
Collapse
|
10
|
Graby J, Khavandi A, Thompson D, Downie P, Antoniades C, Rodrigues JCL. CT coronary angiography-guided cardiovascular risk screening in asymptomatic patients: is it time? Clin Radiol 2021; 76:801-811. [PMID: 34404515 DOI: 10.1016/j.crad.2021.07.010] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2021] [Accepted: 07/13/2021] [Indexed: 12/14/2022]
Abstract
Cardiovascular disease (CVD) is the leading cause of death in the UK, whilst millions live with various forms of the disease. Coronary artery disease constitutes a significant portion of this morbidity and mortality, and is the leading cause of premature death. Increasing focus is thus being placed on the optimisation of CVD prevention, where risk screening plays a key role. Indeed, the decline in age-adjusted cardiovascular mortality achieved up to now has been largely attributed to primary preventative therapies (e.g., statins) introduced earlier in the disease process. National initiatives exist to improve cardiovascular health at a population level, but in its current form, CVD screening at the individual level is predominantly undertaken using multivariate risk scores based on population-based data. These have multiple innate flaws, highlighted in this review. Non-invasive imaging plays a key role in the screening of other disease processes, helping to personalise the screening process. Although the coronary artery calcium score as a screening tool has a role in national and international guidance, whether a shift to screening with computed tomography coronary angiography (CTCA) is now appropriate is open for discussion. Image acquisition techniques continue to improve with reducing radiation exposure and an ever-expanding evidence-base for additional prognostic data offered by CTCA. This enables the potential identification of sub-clinical atherosclerosis, including with novel artificial intelligence techniques. This review aims to report current guidelines regarding cardiac CT imaging in the asymptomatic primary prevention setting, advances in various CT technologies and future opportunities for progress in this field.
Collapse
Affiliation(s)
- J Graby
- Department of Cardiology, Royal United Hospital, Combe Park, Bath, BA1 3NG, UK; Department for Health, University of Bath, Claverton Down, Bath, BA2 7AY, UK
| | - A Khavandi
- Department of Cardiology, Royal United Hospital, Combe Park, Bath, BA1 3NG, UK
| | - D Thompson
- Department for Health, University of Bath, Claverton Down, Bath, BA2 7AY, UK
| | - P Downie
- Department of Laboratory Medicine, Salisbury District Hospital, Odstock Road, Salisbury, SP2 8BJ, UK
| | - C Antoniades
- Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 9DU, UK
| | - J C L Rodrigues
- Department for Health, University of Bath, Claverton Down, Bath, BA2 7AY, UK; Department of Radiology, Royal United Hospital, Combe Park, Bath, BA1 3NG, UK.
| |
Collapse
|
11
|
Murphy D, Graby J, McKenzie D, Kandan SR, Carson K, Lowe R, Khavandi A, Hudson B, Rodrigues J. FFRCT and Invasive Coronary Angiography – assessing concordance in an unselected UK real world population. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background/Introduction
CT coronary angiography (CTCA) Fractional Flow Reserve (FFRCT) is a key investigation in chronic coronary syndrome (CCS) guidelines. FFR calculated from CTCA may help improve CTCA specificity for flow limiting disease, preventing unnecessary invasive coronary angiography (ICA).
Purpose
To (1) assess the treatment planning potential of FFRCT by determining the concordance of FFRCT with an ICA +/− invasive physiological assessment for the detection of flow limiting CAD in a real world NHS setting and (2) concordance sub-analysis of concordance of invasive iFR and FFRCT.
Methods
A single-centre retrospective analysis of a prospectively maintained clinical CTCA database. We identified patients with CCS who had CTCA FFRCT and subsequent ICA from August 2018 to January 2021. Concordance was assessed on a per patient and per vessel basis (major epicardial vessels: left main stem [LMS], left anterior descending artery [LAD], circumflex [LCx], right coronary artery [RCA]). Two non-invasive ischaemia thresholds were examined an FFRCT ≤0.8 and <0.75 (2 cm distal to stenosis). This was compared to a clinical ICA assessment where a flow limiting lesion was defined as a stenosis >70% (or >50% in the LMS) and/or an end vessel iFR ≤0.89 / FFR ≤0.8. All vessels that underwent an iFR, at the interventionists discretion, were then assessed relative to their end-vessel FFRCT.
Results
565 patients had a CTCA with FFRCT and 164 patients had a subsequent ICA and were suitable for analysis. On a per patient basis 69% of those referred to ICA with an FFRCT ≤0.8 of at least one major epicardial vessel had any flow limiting CAD at ICA. With an FFRCT <0.75 this was 73%. Table 1 illustrates the per vessel concordance.
A total of 120 vessels were included in the iFR subsection analysis. The mean FFRCT was 0.71 (±0.13) and mean iFR was 0.89 (±0.1). Accuracy was 54% (95% CI 45–63%) with a sensitivity of 89% (95% CI 76–96%), specificity 32% (95% CI 22–44%), positive predictive value 45% (95% CI 40–50%) and negative predictive value of 83% (95% CI 66–92%). A Pearson's correlation coefficient of 0.23 was found.
Conclusion
This study demonstrated that the negative predictive value of FFRCT was excellent, including importantly for LMS analysis. The specificity on a per vessel basis was good with the exception of the LAD assessment. This may have implications for interventional planning with this imaging modality. FFRCT correlated poorly with invasive iFR in this subsection analysis although selection bias may be contributing. There remains a significant proportion of patients referred for an ICA where no flow limiting CAD is found.
Funding Acknowledgement
Type of funding sources: None. Table 1. Per vessel concordance analysis of potential flow limiting FFRCT relative to clinical ICA findings. Analysed with an ischaemia threshold of FFRCT ≤0.80 and <0.75. PPV = Positive Predictive Value. NPV = Negative Predictive Value.
Collapse
Affiliation(s)
- D Murphy
- Royal United Hospital Bath NHS Trust, Bath, United Kingdom
| | - J Graby
- Royal United Hospital Bath NHS Trust, Bath, United Kingdom
| | - D McKenzie
- Royal United Hospital Bath NHS Trust, Bath, United Kingdom
| | - S R Kandan
- Royal United Hospital Bath NHS Trust, Bath, United Kingdom
| | - K Carson
- Royal United Hospital Bath NHS Trust, Bath, United Kingdom
| | - R Lowe
- Royal United Hospital Bath NHS Trust, Bath, United Kingdom
| | - A Khavandi
- Royal United Hospital Bath NHS Trust, Bath, United Kingdom
| | - B Hudson
- Royal United Hospital Bath NHS Trust, Bath, United Kingdom
| | - J Rodrigues
- Royal United Hospital Bath NHS Trust, Bath, United Kingdom
| |
Collapse
|
12
|
Murphy D, Graby J, Rakhecha T, Donaghue J, McKenzie D, Kandan SR, Khavandhi A, Carson K, Lowe R, Hudson B, Rodrigues J. 169 Real world NHS experience of CTCA with FFRCT for the detection of surgical coronary artery disease - the case for enhanced pre-procedural planning? Imaging 2021. [DOI: 10.1136/heartjnl-2021-bcs.166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
13
|
Sarkar P, Graby J, Walker P, Osman L, Bradley M, Likeman M, Sandeman DR, Sieradzan KA, Rice CM. Response: Implantation/explantation of sEEG electrodes and takotsubo syndrome: Plausible merits of additions to the protocol. Epilepsia Open 2021; 6:450-451. [PMID: 34033233 PMCID: PMC8166784 DOI: 10.1002/epi4.12486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2021] [Accepted: 04/02/2021] [Indexed: 11/11/2022] Open
Affiliation(s)
- Pamela Sarkar
- Southmead Hospital, North Bristol NHS Trust, Bristol, UK.,Queen Elizabeth Hospital, Egbaston, Birmingham, UK
| | - John Graby
- Southmead Hospital, North Bristol NHS Trust, Bristol, UK
| | - Paul Walker
- Southmead Hospital, North Bristol NHS Trust, Bristol, UK
| | - Leyla Osman
- Southmead Hospital, North Bristol NHS Trust, Bristol, UK
| | - Marcus Bradley
- Southmead Hospital, North Bristol NHS Trust, Bristol, UK
| | - Marcus Likeman
- Southmead Hospital, North Bristol NHS Trust, Bristol, UK
| | | | | | - Claire M Rice
- Southmead Hospital, North Bristol NHS Trust, Bristol, UK.,Clinical Neurosciences, Translational Health Sciences, University of Bristol, Bristol, UK
| |
Collapse
|
14
|
Graby J, Goh ZW, Haya N, Carson K. Acute coronary syndrome leading to a new diagnosis of phaeochromocytoma following a profound intraprocedural hypertensive surge. BMJ Case Rep 2021; 14:14/3/e240933. [PMID: 33753390 PMCID: PMC7986864 DOI: 10.1136/bcr-2020-240933] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
Phaeochromocytomas are rare neuroendocrine tumours, which can significantly increase the risk of cardiovascular morbidity and mortality. They are also recognised as 'the great mimic' and can present in many ways. A 42-year-old male patient presented with a non-ST elevation acute coronary syndrome and was medically treated pending an invasive coronary angiogram. During this procedure, he suffered a profound, symptomatic hypertensive surge documented with invasive pressure monitoring. This raised concern for potential secondary causes of hypertension, particularly given his age. He was subsequently diagnosed with a phaeochromocytoma, and after surgical resection of the tumour, his blood pressure control improved and he remains on single therapy only. As clinicians, it is important to remain alert for previously undiagnosed comorbidities contributing to common pathology, including rare, but life-threatening conditions as we present in this case.
Collapse
Affiliation(s)
- John Graby
- Department of Cardiology, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK
| | - Zi Wei Goh
- Department of Endocrinology, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK
| | - Naik Haya
- Department of Endocrinology, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK
| | - Kevin Carson
- Department of Cardiology, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK
| |
Collapse
|
15
|
Sarkar P, Graby J, Walker P, Osman L, Bradley M, Likeman M, Sandeman DR, Sieradzan KA, Rice CM. Takotsubo stress cardiomyopathy following explantation of sEEG electrodes. Epilepsia Open 2021; 6:239-243. [PMID: 33681668 PMCID: PMC7918336 DOI: 10.1002/epi4.12452] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2020] [Revised: 11/03/2020] [Accepted: 11/18/2020] [Indexed: 01/24/2023] Open
Abstract
Objective Takotsubo stress cardiomyopathy is characterized by dysfunction of the left ventricle of the heart including apical ballooning and focal wall-motion abnormalities. Although reported in association with seizures and intracerebral hemorrhage, there are no studies reporting its occurrence in patients having stereoelectroencephalography (sEEG). Methods A 38-year-old lady with no prior history of cardiac disease experienced sudden onset chest pain and acute left ventricular failure 4 hours following explantation of stereoelectroencephalogram electrodes. Results A small parenchymal hematoma related to the right posterior temporal electrode had been noted postelectrode insertion but was asymptomatic. Focal-onset seizures from nondominant mesial temporal structures were recorded during sEEG. Following the presentation with LVF, new-onset anterolateral T-wave inversion with reciprocal changes in leads II, III, and aVF was noted on electrocardiogram (ECG) and the chest X-ray findings were consistent with pulmonary edema. Echocardiography demonstrated hypokinesis of the cardiac apex and septum consistent with Takotsubo stress cardiomyopathy. Significance Awareness of the possible complication of Takotsubo stress cardiomyopathy is required in an epilepsy surgery program.
Collapse
Affiliation(s)
- Pamela Sarkar
- Southmead HospitalNorth Bristol NHS TrustBristolUK
- Queen Elizabeth HospitalEdgbaston, BirminghamUK
| | - John Graby
- Southmead HospitalNorth Bristol NHS TrustBristolUK
| | - Paul Walker
- Southmead HospitalNorth Bristol NHS TrustBristolUK
| | - Leyla Osman
- Southmead HospitalNorth Bristol NHS TrustBristolUK
| | | | | | | | | | - Claire M. Rice
- Queen Elizabeth HospitalEdgbaston, BirminghamUK
- Clinical Neurosciences, Translational Health SciencesUniversity of BristolBristolUK
| |
Collapse
|
16
|
Graby J, Carpenter A, Medland R, Brown S, Sowerby C, Priestman L, Dayer M, Furniss G. P3792The impact of elective cardioversion for atrial fibrillation in heart failure patients. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0637] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Severe left ventricular systolic dysfunction (LVSD) is associated with worse outcomes in heart failure (HF) patients. Persistent atrial fibrillation (AF) is common in this patient group. As part of a nurse-led cardioversion service at a district general hospital we assessed the impact of elective cardioversion (DCCV) for AF in patients with LVSD on their ejection fraction (EF), and compared outcomes in patients selectively pre-treated with amiodarone for their DCCV.
Methods
A retrospective analysis was undertaken of DCCV for AF over 5 years, recording demographic, medication, serial echocardiogram (TTE), and outcome data. Significant LVSD was classified as moderate (ejection fraction [EF] 35–45%) or severe (EF<35%). All patients treated with amiodarone had baseline and serial thyroid, liver, renal function monitored, were counselled on side effects and followed up.
Results
103 patients with significant LVSD and follow-up TTE underwent DCCV, with a median age of 66 (IQR 58–73) and mean CHA2DS2-VASc 2.5. Overall mean baseline EF was 30% (SD ±11), overall follow-up EF (regardless of repeat TTE rhythm) was 42% (SD ±12), and the mean delta EF +12% improvement (SD ±11). At follow-up TTE, 66% (68/103) of patients were in sinus rhythm (SR) and 34% (35/103) in AF. 62/68 (91%) patients in SR at follow-up TTE were also treated with HF medications, vs 33/35 (94%) of those in AF. 61/68 (90%) of patients in SR at follow-up TTE had any improvement in EF vs 21/35 (60%) patients in AF (p=0.0007). For patients in SR the mean baseline EF was 31% (SD ±10) and mean follow-up EF 47% (SD ±9), vs the AF at repeat TTE patients' mean baseline EF 27% (SD ±12) and mean follow-up EF 35% (SD ±13). The mean delta EF of patients still in SR at follow-up scan was 15% (SD ±10) vs 8% (SD ±11) for patients who had reverted to AF (p=0.0004). Prior analysis of our data-set including patients awaiting repeat TTE demonstrated a significant improvement in 6 month AF recurrence rate.
Table 1. Comparing outcomes with amiodarone pre-treatment for patient with follow-up EF data Acute DCCV Success Mean Baseline EF Mean Repeat EF Mean Delta EF AF Recurrence to 6 months Amiodarone 17/17 (100%) 29% (SD 11) 45% (SD 11) 15% (SD 13) 6/17 (35%) No Amiodarone 80/86 (93%) 30% (SD 11) 42% (SD 12) 12% (SD 10) 50/86 (58%) P value 0.59 0.22 0.11
Conclusion
Restoration of SR in a cohort of patients with AF, severe LVSD, on good medical therapy significantly improves left ventricular EF. This reinforces the importance of maintaining SR for HF patients. There was also a trend towards improved medium term outcomes in patients pre-treated with amiodarone. Further study into long-term rhythm control and ablation outcomes is needed.
Collapse
Affiliation(s)
- J Graby
- Musgrove Park Hospital, Taunton, United Kingdom
| | - A Carpenter
- Musgrove Park Hospital, Taunton, United Kingdom
| | - R Medland
- Musgrove Park Hospital, Taunton, United Kingdom
| | - S Brown
- Musgrove Park Hospital, Taunton, United Kingdom
| | - C Sowerby
- Musgrove Park Hospital, Taunton, United Kingdom
| | - L Priestman
- Musgrove Park Hospital, Taunton, United Kingdom
| | - M Dayer
- Musgrove Park Hospital, Taunton, United Kingdom
| | - G Furniss
- Musgrove Park Hospital, Taunton, United Kingdom
| |
Collapse
|
17
|
Graby J, MacConnell T. P5235A technological approach to improving efficiency of primary to secondary care referrals. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Recognised in the 2019 NHS Long-term plan was the need to streamline services, with less face-to-face outpatient (OP) care by utilising digital technology and creating “virtual clinics” (VC). A team of Cardiologists and General Practitioners (GP) collaborated to create a VC via a web-based video link, enabling discussion of patients being considered by primary care for referral to the Cardiology clinic with members of the GP team present to: identify appropriate patients for OP review, enable early selection of investigations, identify patients not requiring further assessment. We aimed to assess the safety and efficacy of this approach.
Methods
VC's were established between a Consultant Cardiologist and two primary care practices. All referrals required an ECG. Each patient was presented by the referring GP, with all others present in the room to enable an educational experience. Consultant Cardiologist issued correspondence and co-ordinated any required tests and follow-up. A 13 month period of this practice was reviewed with 135 patient events screened via a cross-matched record of patients. Data was recorded for: indication for discussion; outcome; likelihood patient would have had test or referral made without this service (as assessed by Cardiology), and whether patients discussed had unplanned admissions or assessments.
Results
8/135 were excluded (duplication; admitted prior to VC; not discussed; re-discussed for learning). Efficacy: The overall number of patients a GP “would” have referred were 113 (89%), and the number “would” have had tests booked 98 (77%), across the two practises. This left an overall OPA post VC of 11% vs potential 89% “would” have been referred (100 potential appointments avoided), and an overall test rate post SAC 48% vs 77% “would” have had tests (37 potential tests avoided).
Safety
Unplanned Cardiology input post-VC included 1 subsequent chest pain clinic (different issue to VC), and 1 admission with syncope (discussed in SAC), with nil found.
Table 1 No Further Input Blood Test Cardiac Test OPA Primary Care 1 21 (40%) 3 (6%) 25 (47%) 4 (7%) Primary Care 2 32 (43%) 0 (0%) 32 (43%) 10 (14%) Overall 53 (42%) 3 (2%) 57 (45%) 14 (11%) Distribution of plan made in VC including: no further input required; blood test in Primary Care; Cardiac test in hospital only; outpatient Cardiology clinic (OPA).
Conclusion
The reduction in OPA and tests demonstrates improvement resource untilsation, and safety data was encouraging. This service demonstrates a novel approach to technology-enabled streamlining of primary to secondary care services in a safe and efficient manner.
Collapse
Affiliation(s)
- J Graby
- Musgrove Park Hospital, Taunton, United Kingdom
| | | |
Collapse
|
18
|
Graby J, Tibbs G, Giblett D, Dayer M, Gosling O. P766The impact of a nurse-led heart failure service on complex device need. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz747.0366] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
The prevalence of left ventricular systolic dysfunction (LVSD) continues to rise. It is recognised that optimal medical therapy can improve ejection fraction (EF) in a proportion of patients. A nurse-led Heart Failure Service (HFS) was established in a district general hospital to deliver this, and previous analysis has demonstrated its efficacy in optimising HF drugs to recognised therapeutic doses.
Complex devices (Implantable Cardiac Defibrillators [ICDs] or Cardiac Re-synchronisation Therapy Devices [CRTs]) are established treatments for HF patients if on Optimal Medical Therapy (OMT). The European Society of Cardiology (ESC) and National Institute for Clinical Excellence (NICE) guidelines have expanded their role with a broad cohort of patients eligible for this therapy.
Aim
We sought to determine how many patients, who at baseline had an indication for device therapy, improved after OMT to an extent that they no longer had an indication for device therapy.
Methods
A retrospective analysis was undertaken of the HFS database over a 5 year period recording ECG for QRS duration & morphology, surveillance of EF, device outcome. Exclusion criteria: Baseline EF >35%; device in-situ or listed for prior to HFS referral; no identifiable baseline EF or ECG.
Results
502 patients were analysed and 264 patients met criteria for a new device or upgrade at baseline – 191 male (72%), 73 female (28%), median age 73 (IQR 64–80).
76/97 (78%) of potential CRT candidates (Pacing or Defibrillator component) were male. 16/97 (16%) improved to an EF >35% (median age 68 [IQR 64–72], 14 male [88%], 2 female [12%]). 4/16 (25%) of these patients underwent pharmacological or electrical cardioversion, which can contribute to EF improvement.
There were 167 potential ICD candidates (115 male [69%]). 53 /167 (32%) improved to an EF >35% (median age 68 [IQR 56–75], 33 male [61%]). 7/53 (13%) of these patients had other treatments that can also improve EF (cardioversion, 4; re-vascularisation, 2; valvuloplasty, 1).
69/264 (26.1%) patients did not require a device after optimal therapy had been delivered.
Conclusions
We have demonstrated that in a significant proportion of HFS patients, the delivery of high quality OMT translates into an improvement in EF.
Not all patients that strictly “meet guideline criteria” will be offered a device, nor will all patients take up offer of a device. However, this improvement in EF is likely to benefit the patient symptomatically and prognostically, and carry a significant cost saving to healthcare institutions. A cost analysis study will be undertaken to further assess this.
Collapse
Affiliation(s)
- J Graby
- Musgrove Park Hospital, Cardiology, Taunton, United Kingdom
| | - G Tibbs
- Musgrove Park Hospital, Cardiology, Taunton, United Kingdom
| | - D Giblett
- Musgrove Park Hospital, Cardiology, Taunton, United Kingdom
| | - M Dayer
- Musgrove Park Hospital, Cardiology, Taunton, United Kingdom
| | - O Gosling
- Musgrove Park Hospital, Cardiology, Taunton, United Kingdom
| |
Collapse
|
19
|
Vadhwana B, Graby J, Lewis M, Goldman A, Sergot A, Ramsey C, Monahan KJ. Predictors of abnormalities on magnetic resonance cholangiopancreatography: is there a role when the biliary tree is normal on previous imaging? Ann Gastroenterol 2019; 32:193-198. [PMID: 30837793 PMCID: PMC6394272 DOI: 10.20524/aog.2019.0352] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/19/2018] [Accepted: 12/17/2018] [Indexed: 11/26/2022] Open
Abstract
Background There is limited evidence supporting the use of magnetic resonance cholangiopancreatography (MRCP) if the biliary tree is within normal limits on ultrasound scan (US) or computed tomography (CT). The aim of this study was to assess the role of MRCP in the absence of a dilated biliary system on index imaging. Methods A retrospective observational study of consecutive MRCP investigations (n=427) was performed between October 2010 and June 2013 at a single district general hospital. Data collected included patient demographics, clinical presentation, liver function tests (LFTs) and radiological presence of stones. Binary logistic regression and chi-square test were performed using SPSS v23. Results We included 358 cases, 65% female (n=231) and 35% male (n=127), with a mean age of 60 years. Of these, 63% presented with abdominal pain (n=225), with 20% having concurrent deranged LFTs (n=44) and 8% jaundice (n=18). Index imaging demonstrated a dilated biliary system >6 mm in 68% (n=245). Alkaline phosphatase (ALP) elevation was an independent positive predictor for an abnormal MRCP (P=0.003). Abnormal index imaging, ALP and clinical jaundice were all significantly associated with a positive MRCP (P<0.001, P=0.028, P=0.018). Conclusions It is efficacious to proceed to MRCP with abnormal findings on index imaging, clinical jaundice or elevated ALP. An MRCP scan should be strongly considered in the context of elevated ALP and normal US/CT biliary system.
Collapse
Affiliation(s)
- Bhamini Vadhwana
- Department of Gastroenterology (Bhamini Vadhwana, John Graby, Martin Lewis, Anouchka Goldman, Kevin J. Monahan)
- Correspondence to: Bhamini Vadhwana, Department of Gastroenterology, West Middlesex University Hospital, Twickenham Road, Isleworth TW7 6AF, UK, e-mail:
| | - John Graby
- Department of Gastroenterology (Bhamini Vadhwana, John Graby, Martin Lewis, Anouchka Goldman, Kevin J. Monahan)
| | - Martin Lewis
- Department of Gastroenterology (Bhamini Vadhwana, John Graby, Martin Lewis, Anouchka Goldman, Kevin J. Monahan)
| | - Anouchka Goldman
- Department of Gastroenterology (Bhamini Vadhwana, John Graby, Martin Lewis, Anouchka Goldman, Kevin J. Monahan)
| | - Antoni Sergot
- Radiology (Antoni Sergot, Catherine Ramsey), West Middlesex University Hospital, Twickenham Road, Isleworth TW7 6AF, UK
| | - Catherine Ramsey
- Radiology (Antoni Sergot, Catherine Ramsey), West Middlesex University Hospital, Twickenham Road, Isleworth TW7 6AF, UK
| | - Kevin J. Monahan
- Department of Gastroenterology (Bhamini Vadhwana, John Graby, Martin Lewis, Anouchka Goldman, Kevin J. Monahan)
| |
Collapse
|
20
|
Graby J, Ramsey C, McPhail M, Goldman A, Monahan K. The role of MRCP in potential gallstone disease when the biliary tree is normal on initial imaging. Clin Radiol 2015. [DOI: 10.1016/j.crad.2015.06.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
21
|
Ahmad Y, Nijjer S, Cook CM, El-Harasis M, Graby J, Petraco R, Kotecha T, Baker CS, Malik IS, Bellamy MF, Sethi A, Mikhail GW, Al-Bustami M, Khan M, Kaprielian R, Foale RA, Mayet J, Davies JE, Francis DP, Sen S. A new method of applying randomised control study data to the individual patient: A novel quantitative patient-centred approach to interpreting composite end points. Int J Cardiol 2015; 195:216-24. [PMID: 26048380 DOI: 10.1016/j.ijcard.2015.05.109] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/29/2015] [Accepted: 05/06/2015] [Indexed: 01/09/2023]
Abstract
BACKGROUND Modern randomised controlled trials typically use composite endpoints. This is only valid if each endpoint is equally important to patients but few trials document patient preference and seek the relative importance of components of combined endpoints. If patients weigh endpoints differentially, our interpretation of trial data needs to be refined. METHODS AND RESULTS We derive a quantitative, structured tool to determine the relative importance of each endpoint to patients. We then apply this tool to data comparing angioplasty with drug-eluting stents to bypass surgery. The survey was administered to patients undergoing cardiac catheterisation. A meta-analysis comparing coronary artery bypass grafting (CABG) to percutaneous coronary interventuin (PCI) was then performed using (a) standard MACE and (b) patient-centred MACE. Patients considered stroke worse than death (stroke 102.3 ± 19.6%, p < 0.01), and MI and repeat revascularisation less severe than death (61.9 ± 26.8% and 41.9 ± 25.4% respectively p < 0.01 for both). 7 RCTs (5251 patients) were eligible. Meta-analysis demonstrated that standard MACE occurs more frequently with PCI than surgery (OR 1.44; 95% CI 1.10 to 1.87; p = 0.007). Re-analysis using patient-centred MACE found no significant difference between PCI and CABG (OR 1.22, 95% CI 0.97 to 1.53; p = 0.10). CONCLUSIONS Patients do not consider the constituent endpoints of MACE equal. We derive a novel patient-centred metric that recognises and quantifies the differences attributed to each endpoint. When patient preference data are applied to contemporary trial results, there is no significant difference between PCI and CABG. Responses from individual patients in clinic could be used to give individual patients a recommendation that is truly personalised.
Collapse
Affiliation(s)
- Yousif Ahmad
- International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, 59-61 North Wharf Road, London W2 1LA, UK
| | - Sukhjinder Nijjer
- International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, 59-61 North Wharf Road, London W2 1LA, UK
| | - Christopher M Cook
- International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, 59-61 North Wharf Road, London W2 1LA, UK
| | - Majd El-Harasis
- International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, 59-61 North Wharf Road, London W2 1LA, UK
| | - John Graby
- International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, 59-61 North Wharf Road, London W2 1LA, UK
| | - Ricardo Petraco
- International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, 59-61 North Wharf Road, London W2 1LA, UK
| | - Tushar Kotecha
- International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, 59-61 North Wharf Road, London W2 1LA, UK
| | - Christopher S Baker
- International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, 59-61 North Wharf Road, London W2 1LA, UK
| | - Iqbal S Malik
- International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, 59-61 North Wharf Road, London W2 1LA, UK
| | - Michael F Bellamy
- International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, 59-61 North Wharf Road, London W2 1LA, UK
| | - Amarjit Sethi
- International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, 59-61 North Wharf Road, London W2 1LA, UK
| | - Ghada W Mikhail
- International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, 59-61 North Wharf Road, London W2 1LA, UK
| | - Mahmud Al-Bustami
- International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, 59-61 North Wharf Road, London W2 1LA, UK
| | - Masood Khan
- International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, 59-61 North Wharf Road, London W2 1LA, UK
| | - Raffi Kaprielian
- International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, 59-61 North Wharf Road, London W2 1LA, UK
| | - Rodney A Foale
- International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, 59-61 North Wharf Road, London W2 1LA, UK
| | - Jamil Mayet
- International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, 59-61 North Wharf Road, London W2 1LA, UK
| | - Justin E Davies
- International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, 59-61 North Wharf Road, London W2 1LA, UK
| | - Darrel P Francis
- International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, 59-61 North Wharf Road, London W2 1LA, UK
| | - Sayan Sen
- International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, 59-61 North Wharf Road, London W2 1LA, UK.
| |
Collapse
|